InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Updates Shareholders on Major Milestones, Expands Clinical Trial Sites and Secures $8M Funding in 2024

October 30, 2024 07:50:00

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotech firm developing gamma-delta T cell therapies, reported key 2024 achievements, highlighting progress in the ACHIEVE UK trial, with eight patients dosed and new trial sites established, including Guy’s and St. Thomas Hospital. The company also launched a compassionate use program for TCB008 and signed two non-binding LOIs for potential acquisitions in CAR-T and NK therapy technologies. TC BioPharm collaborated with the University of Surrey on preclinical Mpox studies and partnered with Carnegie Mellon University on AI-driven donor screening for cell therapies. Cost efficiencies have increased treatment capacity, while a Q3 capital raise of $8 million bolstered its balance sheet, positioning TC BioPharm to continue advancing its strategic initiatives into 2025.

To view the full press release, visit: https://ibn.fm/xoQlF

About TC BioPharm Holdings PLC

TC BioPharm is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line – Phase 2b/3 pivotal trial for OmnImmune(R) in treatment of acute myeloid leukemia using the company’s proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. For more information about the company, visit www.tcbioparm.com.

NOTE TO INVESTORS: The latest news and updates relating to TCBP are available in the company’s newsroom at https://ibn.fm/TCBP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN